- TCR BCR
As France's leading biocluster, Genopole is an incubator for cutting-edge projects in biotechnology. Located in the city of Évry, just south of Paris, Genopole provides a unique environment for scientists and entrepreneurs seeking to advance research and innovation.Discover >
Giving wings to research and empowering employment in our community are cornerstones of Genopole's mission. Catch up on recent scientific advances, the accomplishments of our biotech actors and the events that enliven the biocluster.Discover >
Wiratech Europe is a healthcare company that uses scientific knowledge of human variability and instrumental technologies to provide innovative tests, devices and services.
Wiratech is specialized in next generation sequencing (NGS) and has acquired expertise in immunogenetic analysis. The company has developed a human leukocyte antigen (HLA) NGS technology and transferred it to many medical labs in Europe and Asia.
Wiratech is at the forefront of T-cell (TCR) and B-cell receptor (BCR) NGS expertise as applied to cancers, autoimmune diseases and transplantations. It furthermore intends to extend its expertise to psychiatric disorders and TCR-HLA interaction regulation.
Wiratech Europe was created in 2010 by Sami Djoulah, a geneticist trained under the supervision of Nobel Prize laureate Professor Jean Dausset. Sami Djoulah is an avid bio-entrepreneur. He received a Best New Company award in 2011 and a Business Creation prize in 2012. His areas of interest are precision medicine and personalized diagnosis in transplantation and immunotherapy.
In France, Sami Djoulah helped draft the Genomic Medicine France 2025 plan. Furthermore, in 2016, thanks to a collaborative study with the greater Paris public hospital system (AP-HP), Wiratech was chosen by authorities from the EU and the Ile-de-France administrative region to receive a European Regional Development Fund (ERDF). Finally, several research programs are being developed jointly with the Medicen competitiveness cluster and other institutes.
DESCRIPTION OF THE PRODUCTS / SERVICES / TECHNOLOGY
CUSTOMER REFERENCES / COLLABORATIONS / HIGHLIGHTS
Beyond its status as an ERDF recipient and its collaborations with AP-HP, the Medicen competitiveness cluster and other institutes, Wiratech is also active on the international front. The company is working on major translational research programs in China, particularly in the field of lung cancer in Wuhan. Sami Djoulah also co-chairs the TCR / HLA immune interaction study underway at Stanford University in California (USA), and is furthermore involved in a national program of genomic medicine in Algeria. Wiratech is also participating in an immunotherapy research program in Romania.
In same field
– Characterization of antigen / antibody interactions (epitope / paratope) – Optimization of therapeutic antibodiesDiscover
At Phagos, we use bacteria’s natural predator, the bacteriophage, to overcome infectious diseases in aquaculture.Discover
Biotechnology, R&D, Drug development, oncology, obesity, infectious diseasesDiscover
Production of BCG vaccines and BCG-based cancer and inflammation treatments, preparation and distribution of fresh log-phase BCG cultures.Discover
Synsight is a company specializing in the discovery and preclinical development of new therapeutic molecules, based on a proprietary, integrated platform, combining artificial intelligence, molecular modeling and a functional experimental screening approach of High-Content Screening (HCS ).Discover
Santen SAS has developed its own sales force to commercialize ophthalmic products in France while Novagali Innovation Center is a center of excellence for Santen Group dedicated to research and development of innovative ophthalmic treatments for all segments of the eye.Discover
R & D services in the field of transient expression of recombinant proteins in plants.Discover
Pharnext develops new therapies and biomarkers based on network pharmacology with a proprietary discovery platform. The company is focused on pathologies with high unmet medical needs. These include neurodegenerative, orphan and common diseases (Charcot-Marie-Tooth disease Type 1A, Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS)).Discover
Pharming specializes in the production of recombinant proteins in transgenic rabbit milk.Discover
PEP-Therapy develops innovative peptides as targeted therapies in oncology. The company operates a unique therapeutic technology based on cell penetrating & interfering peptides (CP&IP). These innovative molecules penetrate cells and specifically block relevant intracellular protein-protein interactions, thus inhibiting key pathological mechanisms.Discover
GenoSafe is a full contract research and consulting organization specialized in evaluating the quality, safety and efficacy of innovative biological products. Our goal is to enable our clients to move their products along clinical development rapidly and efficiently.Discover
Discovery, development and production of innovative therapies for rare genetic diseases, notably neuromuscular diseases.Discover
Synthetic gene therapy for the treatment of severe human liver diseases and tools for the bioproduction of recombinant proteins and viruses using the proprietary expression system C3P3.Discover
Enterome develops and commercializes therapies for disorders associated with disruption of the intestinal microbiota.Discover
Research, development and commercialization of tyrosine kinase inhibitors as targeted therapy for pathologies with unmet medical needs.Discover